

TN-1375


N-Nitroso Desmethyl Doxepin Analysis using a SCIEX 5500+ System

Pankaj Partani¹, Rahul Baghla², Sean Orlowicz³

¹SCIEX Lab, Hitech Defence and Aerospace Park Industrial Area, Mahadeva Kodigehalli, Jala Taluka, Bengaluru 562149

²AB Sciex LLC, 500 Old Connecticut Path, Framingham, MA 01701, USA

³Phenomenex Inc, 411 Madrid Ave., Torrance, CA 90501, USA




Introduction

Desmethyl Doxepin is a tricyclic antidepressant that acts as a norepinephrine reuptake inhibitor. It has been determined to be the major active metabolite of Doxepin and is more potent than Doxepin alone. Due to the fact that it is a secondary amine, it is possible that an N-nitroso Desmethyl Doxepin impurity (NDSRI – nitroso drug substance related impurity) can form during synthesis or storage. As NDSRIs have the potential to be carcinogenic it is important to monitor the active pharmaceutical compound or formulations for the presence of the NDSRI. In this technical note, a method is described where N-nitroso Desmethyl Doxepin is separated from the parent drug, allowing for sensitive detection by LC-MS/MS.

Sample Preparation

Standard preparation (Impurity). 5 mg of the impurity was dissolved in 5 mL of Acetonitrile to prepare a stock solution of 1000 PPM concentration.

Drug product sample preparation (Doxepin HCl 5% cream). 20 mg of cream base corresponds to ~1 mg of doxepin hydrochloride and was dissolved in 1.0 mL of Methanol. The sample was vortexed for 10-15 min. The sample was later centrifuged at 14000 rpm at 5°C and the supernatant filtered using a 0.22 µm PVDF syringe filter. The sample was then transferred into an autosampler glass vial for analysis



N-Nitroso desmethyl doxepin

Molecular Formula: C₁₈H₁₈N₂O₂

Monoisotopic m/z: 294.14

LC Conditions

Column: Kinetex Biphenyl 2.6 µ

Dimensions: 150 x 3.0 mm

Part No.: 00F-4622-Y0

Mobile Phase: A: 1 mM Ammonium formate with 0.1% formic acid in Water
B: 0.1% formic acid in Methanol

Gradient:	Time (min)	% B
	0.00	40
	4.00	40
	6.00	65
	9.00	65
	11.00	70
	19.00	70
	20.00	95
	22.00	95
	22.10	40
	25.00	40

Valve Method: 0.0 – 0.5 & 11.0-19.0 min (Flow diverted to MS)
0.5-11 & 19.0-24.0 min (Flow diverted to Waste)

Flow Rate: 0.5 mL/min

Injection Volume: 10 µL

Temperature: 40° C

LC System: EXION LC 30 AD

Detection: MS/MS

Detector: SCIEX 5500+

MS/MS Conditions

Ion Source: ESI

Polarity: Positive

Source Temperature: 550° C

GS1: 85

GS2: 80

CUR: 40

IS: 5500

CUR: 40

CAD: 8

Table 1. MS Transitions.

Analyte	Q1 Mass (Da)	Q3 Mass (Da)
N-Nitroso Desmethyl Doxepin-01	295.1	265.2
N-Nitroso Desmethyl Doxepin-02	295.1	250.2
N-Nitroso Desmethyl Doxepin-03	295.1	236.2
N-Nitroso Desmethyl Doxepin-04	295.1	174.2

Table 2. Recovery Results in Doxepin Sample.

Average are observed in control samples (N=3)					ND			
Area count observed for standard sample					Area count observed for spiked API samples			
	Limit of Quantitation	STD-2	STD-3	Specification Standard	Limit of Quantitation	STD-2	STD-3	2x Higher Specification
Inj. No.	(0.0024 PPM)	(0.006 PPM)	(0.015 PPM)	(0.030 PPM)	(0.0053 PPM)	(0.006 PPM)	(0.015 PPM)	(0.133 PPM)
	0.0024 ng/mL	0.006 ng/mL	0.015 ng/mL	0.030 ng/mL	0.0024 ng/mL	0.006 ng/mL	0.015 ng/mL	0.030 ng/mL
1	1977	4461	10679	21630	1478	4908	10360	18973
2	2191	4190	10780	21184	1402	4914	10252	19116
3	1674	4412	11028	20915	1473	4935	9991	19818
4	1457	-	-	20956	1537	-	-	19416
5	1864	-	-	22612	1275	-	-	20190
6	1889	-	-	20193	1501	-	-	19352
Average	1842.0	4354.3	10829.0	21248.3	1444.3	4919.0	10201.0	19477.5
STDEV (%)	252.65	144.41	179.59	814.82	94.05	14.18	189.71	453.5
% CV	13.72	3.32	1.66	3.83	6.51	0.29	1.86	2.33
% Recovery	% Recovery = Area Observed in Rec Samples/Area Observed in Neat Standards				78.39	112.97	94.2	91.67

Figure 1. Representative Spectra for UV and XIC Data: Standard





Figure 2. Linearity data: N-Nitroso Desmethyl Doxepin




Results and Discussion

Kinetex Biphenyl was selected for the separation due to the polar aromatic nature of the stationary phase. Interactions with the N-nitroso group on the target analyte increase retention of the impurity, providing excellent resolution from the parent drug molecule. This allows the desmethyl doxepin, present in excess, to be directed to waste which aids in keeping the first quadrupole clean in the MS/MS system. As shown in Table 2, the Limit of Quantitation for N-Nitroso Desmethyl Doxepin was 0.0024 ng/mL and was maintained in API samples. Good linearity (Figure 2) and %CVs were maintained to produce a robust and reproducible method. As can be seen in Figure 1, additional specificity and sensitivity was achieved by utilizing LC-MS/MS. The core-shell morphology of the Kinetex Biphenyl column provided high efficiency meaning that the N-Nitroso Desmethyl Doxepin peak exhibited a narrow peak width, ensuring that peak height was maximized. This peak height, combined with the sensitive MS/MS detector, provided the excellent limit of quantitation reported.

As regulatory agencies issue guidance recommending that manufacturers of APIs and Drug Products take steps to detect and prevent unacceptable levels of N-Nitrosamine(s) impurities, as well as NDSRIs in drug product(s), increasingly selective and sensitive analytical methods will be necessary. In this Technical Note, we demonstrate such a method utilizing the chromatographic selectivity of Kinetex Biphenyl and the sensitivity of the SCIEX 5500 system.

Figure 3. Representative Chromatograms



Kinetex™ Ordering Information

Phases	2.6 µm Midbore™ Columns (mm)			SecurityGuard™ ULTRA Cartridges (mm)‡		
	30 x 3.0	50 x 3.0	75 x 3.0	100 x 3.0	150 x 3.0	3/pk
EVO C18	00A-4725-Y0	00B-4725-Y0	—	00D-4725-Y0	00F-4725-Y0	AJ0-9297
PS C18	00A-4780-Y0	00B-4780-Y0	—	00D-4780-Y0	00F-4780-Y0	AJ0-8950
Polar C18	—	00B-4759-Y0	—	00D-4759-Y0	00F-4759-Y0	AJ0-9531
Biphenyl	—	00B-4622-Y0	—	00D-4622-Y0	00F-4622-Y0	AJ0-9208
XB-C18	00A-4496-Y0	00B-4496-Y0	00C-4496-Y0	00D-4496-Y0	00F-4496-Y0	AJ0-8775
C18	00A-4462-Y0	00B-4462-Y0	00C-4462-Y0	00D-4462-Y0	00F-4462-Y0	AJ0-8775
C8	00A-4497-Y0	00B-4497-Y0	00C-4497-Y0	00D-4497-Y0	00F-4497-Y0	AJ0-8777
HILIC	00A-4461-Y0	—	—	00D-4461-Y0	00F-4461-Y0	AJ0-8779
Phenyl-Hexyl	—	00B-4495-Y0	—	00D-4495-Y0	00F-4495-Y0	AJ0-8781
F5	—	00B-4723-Y0	—	00D-4723-Y0	00F-4723-Y0	AJ0-9321

for 3.0 mm ID

‡SecurityGuard ULTRA Cartridges require holder, Part No.: [AJ0-9000](#)

Need a different column size or sample preparation format?

No problem! We have a majority of our available dimensions up on www.phenomenex.com, but if you can't find what you need right away, our super helpful Technical Specialists can guide you to the solution via our online chat portal www.phenomenex.com/Chat.

Australia

t: +61 (0)2-9428-6444
auinfo@phenomenex.com

Austria

t: +43 (0)1-319-1301
anfrage@phenomenex.com

Belgium

t: +32 (0)2 503 4015 (French)
t: +32 (0)2 511 8666 (Dutch)
beinfo@phenomenex.com

Canada

t: +1 (800) 543-3681
info@phenomenex.com

China

t: +86 400-606-8099
cninfo@phenomenex.com

Czech Republic

t: +420 272 017 077
cz-info@phenomenex.com

Denmark

t: +45 4824 8048
nordicinfo@phenomenex.com

Finland

t: +358 (0)9 4789 0063
nordicinfo@phenomenex.com

France

t: +33 (0)1 30 09 21 10
franceinfo@phenomenex.com

Germany

t: +49 (0)6021-58830-0
anfrage@phenomenex.com

Hong Kong

t: +852 6012 8162
hkinfo@phenomenex.com

India

t: +91 (0)40-3012 2400
indiainfo@phenomenex.com

Indonesia

t: +62 21 3952 5747
indoinfo@phenomenex.com

Ireland

t: +353 (0)1 247 5405
eireinfo@phenomenex.com

Italy

t: +39 051 6327511
italiainfo@phenomenex.com

Japan

t: +81 (0) 120-149-262
jpinfo@phenomenex.com

Luxembourg

t: +31 (0)30-2418700
nlinfo@phenomenex.com

Mexico

t: 01-800-844-5226
tecnicomx@phenomenex.com

The Netherlands

t: +31 (0)30-2418700
nlinfo@phenomenex.com

New Zealand

t: +64 (0)9-4780951
nzinfo@phenomenex.com

Norway

t: +47 810 02 005
nordicinfo@phenomenex.com

Poland

t: +48 22 51 02 180
pl-info@phenomenex.com

Portugal

t: +351 221 450 488
ptinfo@phenomenex.com

Singapore

t: 800-852-3944
sginfo@phenomenex.com

Slovakia

t: +420 272 017 077
sk-info@phenomenex.com

Spain

t: +34 91-413-8613
espinfo@phenomenex.com

Sweden

t: +46 (0)8 611 6950
nordicinfo@phenomenex.com

Switzerland

t: +41 (0)61 692 20 20
swissinfo@phenomenex.com

Taiwan

t: +886 (0) 0801-49-1246
twinfo@phenomenex.com

Thailand

t: +66 (0) 2 566 0287
thaiinfo@phenomenex.com

United Kingdom

t: +44 (0)1625-501367
ukinfo@phenomenex.com

USA

t: +1 (310) 212-0555
info@phenomenex.com

🌐 **All other countries/regions
Corporate Office USA**

t: +1 (310) 212-0555
www.phenomenex.com/chat

www.phenomenex.com

Phenomenex products are available worldwide. For the distributor in your country/region, contact Phenomenex USA, International Department at international@phenomenex.com

**BE-HAPPY™
GUARANTEE**

Your happiness is our mission. Take 45 days to try our products. If you are not happy, we'll make it right.

www.phenomenex.com/behappy

Subject to Phenomenex Standard Terms and Conditions, which may be viewed at www.phenomenex.com/phx-terms-and-conditions-of-sale. Strata, Kinetex, Luna, MidBore, SecurityGuard, and BE-HAPPY are trademarks of Phenomenex. Agilent is a registered trademark of Agilent Technologies, Inc. SCIEX is a registered trademark and Triple Quad is a trademark of AB SCIEX Pte. Ltd. Comparative separations may not be representative of all applications. Phenomenex is in no way affiliated with Agilent Technologies, Inc. SecurityGuard is patented by Phenomenex. U.S. Patent No. 6,162,362. CAUTION: this patent only applies to the analytical-sized guard cartridge holder, and does not apply to SemiPrep, PREP, or ULTRA holders, or to any cartridges. Strata-X is patented by Phenomenex. U.S. Patent No. 7,119,145. FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures.

© 2025 Phenomenex, Inc. All rights reserved.

